Cognizant entered into a multi-year agreement with AstraZeneca to provide comprehensive biostatistics and medical reporting services to generate clinical study reports. Cognizant will provide centralized statistical programming, statistical analysis, medical writing, and document publishing services, from case report forms to clinical study reports, with the goal of increasing operational efficiency, reducing cycle times, and optimizing costs. AstraZeneca will continue to own and manage key scientific and medical activities associated with the design of clinical trial programs, and the interpretation of data.
 
Cognizant will use its Web 2.0-based platform, Cognizant 2.0, to support knowledge sharing and collaboration across global teams, allowing clinical studies across different countries to be managed simultaneously.
 
“Cognizant will help us streamline our clinical development operations. This is key to our business transformation aimed at achieving greater efficiency, agility, flexibility, and global competitiveness – all of which are crucial to clinical trials and development of new drugs,” said Karin Wingstrand, vice president and head of clinical development at AstraZeneca.
 
“We are pleased to have been selected by AstraZeneca to provide biostatistics and medical reporting services,” said Krish Venkat, senior vice president of the Healthcare and Life Sciences practice at Cognizant. “We are strongly committed to leveraging the domain and process knowledge of our experienced biostatisticians and medical writers to support AstraZeneca through improved decision-making, process standardization, consistency of delivery, and cost savings, which they can reinvest to support the fast, innovative, and efficient development of their R&D programs.”